Gene polymorphisms and pharmacogenetics in Rheumatoid Arthritis;Polimorfismos genéticos y farmacogenética en la artritis reumatoide

Reumatologia Clinica

Volumn 5, Issue 6, 2009, Pages 268-279

  Rego Pérez, Ignacio ^a   Fernández Moreno, Mercedes ^a   Carreira García, Vanessa ^a   Blanco, Francisco J ^a  

^a Laboratorio de Investigación   (Spain)

Author keywords

Cytokines; Gene polymorphisms; Interleukin 1; Pharmacogenetics; Pharmacogenomics; Rheumatoid Arthritis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR;

CLINICAL FEATURE; DISEASE COURSE; DNA POLYMORPHISM; DRUG EFFECT; DRUG MECHANISM; GENETIC VARIABILITY; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; PHARMACOGENETICS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 70449720687     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2008.12.001     Document Type: Review

References (110)

1. Evans W.E., and Relling M.V. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286 (1999) 487-491
2. Silman A.J., MacGregor A.J., Thomson W., Holligan S., Carthy D., Farhan A., et al. Twin concordance rates for rheumatoid arthritis: Results from a nationwide study. Br J Rheumatol 32 10 (1993) 903-907
3. Cornelis F., Fauré S., and Martínez M. Rheumatoid arthritis genome scan and pretative autoimmunity locus. Arthritis Reum 40 (1997) S329
4. Pierik M., Rutgeerts P., Vlietinck R., and Vermeire S. Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol 12 23 (2006) 3657-3667
5. Nepom G.T. Major histocompatibility complex-directed susceptibility to rheumatoid arthritis. Adv Immunol 68 (1998) 315-332
6. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14 (1996) 397-440
7. Deighton C.M., Walker D.J., Griffiths I.D., and Roberts D.F. The contribution of HLA to rheumatoid arthritis. Clin Genet 36 3 (1989) 178-182
8. Gregersen P.K., Silver J., and Winchester R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30 11 (1987) 1205-1213
9. McGregor A., Ollier W., Thomson W., Jawaheer D., and Silman A. HLA-DRB1 *0401/0404 genotype and rheumatoid arthritis: Increased association in men, young age at onset, and disease severity. J Rheumatol 22 (1995) 1032-1036
10. Reveille J.D. Genetic studies in the rheumatic diseases: Present status and implications for the future. J Rheumatol 72 Suppl (2005) 10-13
11. Martínez A., Salido M., Bonilla G., Pascual-Salcedo D., Fernández-Arquero M., De Miguel S., et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 50 4 (2004) 1077-1082
12. Padyukov L., Lampa J., Heimburger M., Ernestam S., Cederholm T., Lundkvist I., et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 62 6 (2003) 526-529
13. Brennan F.M., Maini R.N., and Feldmann M. TNF alpha -a pivotal role in rheumatoid arthritis?. Br J Rheumatol 31 5 (1992) 293-298
14. Smith C.A., Farrah T., and Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 76 6 (1994) 959-962
15. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10 (1992) 411-452
16. Verweij C.L. Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis. Ann Rheum Dis 58 Suppl I (1999) I20-I26
17. Campbell R.D., and Trowsdale J. Map of the human MHC. Immunol Today 14 7 (1993) 349-352
18. Wilson A.G., De Vries N., Pociot F., Di Giovine F.S., Van der Putte L.B., and Duff G.W. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177 2 (1993) 557-560
19. Jacob C.O., Fronek Z., Lewis G.D., Koo M., Hansen J.A., and McDevitt H.O. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: Relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 87 3 (1990) 1233-1237
20. Brinkman B.M., Huizinga T.W., Kurban S.S., Van der Velde E.A., Schreuder G.M., Hazes J.M., et al. Tumor necrosis factor alpha gene polymorphisms in rheumatoid arthritis: Association with susceptibility to, or severity of disease?. Br J Rheumatol 36 5 (1997) 516-521
21. Udalova I.A., Richardson A., Denys A., Smith C., Ackerman H., Foxwell B., et al. Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol 20 24 (2000) 9113-9119
22. Newton J., Brown M.A., Milicic A., Ackerman H., Darke C., Wilson J.N., et al. The effect of HLA-DR on susceptibility to rheumatoid arthritis is influenced by the associated lymphotoxin alpha-tumor necrosis factor haplotype. Arthritis Rheum 48 1 (2003) 90-96
23. Kuo N.W., Lympany P.A., Menezo V., Lagan A.L., John S., Yeo T.K., et al. TNF-857T, a genetic risk marker for acute anterior uveitis. Invest Opthalmol Vis Sci 46 5 (2005) 1565-1571
24. Akman A., Sallakci N., Coskun M., Bacanli A., Yavuzer U., Alpsoy E., et al. TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behcet's disease. Br J Dermatol 155 2 (2006) 350-356
25. Smerdel A., Lie B.A., Ploski R., Koeleman B.P., Forre O., Thorsby E., et al. A gene in the telomeric HLA complex distinct from HLA-A is involved in predisposition to juvenile idiopathic arthritis. Arthritis Rheum 46 6 (2002) 1614-1619
26. Santee S.M., and Owen-Schaub L.B. Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. J Biol Chem 271 (1996) 21151-21159
27. Ranganathan P. Pharmacogenetics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics 6 5 (2005) 481-490
28. Udalova I.A., Nedospasov S.A., Webb G.C., Chaplin D.D., and Turetskaya R.L. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics 16 (1993) 180-186
29. Mulcahy B., Waldron-Lynch F., McDermott M.F., Adams C., Amos C.I., Zhu D.K., et al. Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am J Hum Genet 59 (1996) 676-683
30. Van den Berg W.B. Arguments for interleukin 1 as a target in chronic arthritis. Ann Rheum Dis 59 Suppl I (2000) I81-I84
31. Nicklin M.J., Weith A., and Duff G.W. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 19 2 (1994) 382-384
32. Cox A., Camp N.J., Nicklin M.J., Di Giovine F.S., and Duff G.W. An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers. Am J Hum Genet 62 5 (1998) 1180-1188
33. McDowell T.L., Symons J.A., Ploski R., Forre O., and Duff G.W. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 38 2 (1995) 221-228
34. Van den Velden P.A., and Reitsma P.H. Amino acid dimorphism in IL1A is detectable by PCR amplification. Hum Mol Genet 2 10 (1993) 1753
35. Di Giovine F.S., Takhsh E., Blakemore A.I., and Duff G.W. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet 1 6 (1992) 450
36. Pociot F., Molvig J., Wogensen L., Worsaae H., and Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 22 6 (1992) 396-402
37. Di Giovine FS, Camp NJ, Cox A. Detection and population analysis of IL-1 and TNF gene polymorphisms. In: Balkwill F, editor. Cytokine Molecular Biology. Oxford: Oxford University Press; 2000. p. 21-46.
38. Cantagrel A., Navaux F., Loubet-Lescoulie P., Nourhashemi F., Enault G., Abbal M., et al. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: Relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 42 6 (1999) 1093-1100
39. Buchs N., Di Giovine F.S., Silvestre T., Vannier E., Duff G.W., and Miossec P. IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: Interaction with their plasma levels. Genes Immun 2 4 (2001) 222-228
40. Santtila S., Savinainen K., and Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 47 3 (1998) 195-198
41. Hulkkonen J., Laippala P., and Hurme M. A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals. Eur Cytokine Netw 11 2 (2000) 251-255
42. Dominici R., Cattaneo M., Malferrari G., Archi D., Mariani C., Grimaldi L.M., et al. Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-2 alpha. Immunogenetics 54 (2002) 82-86
43. Whyte M., Hubbard R., Meliconi R., Whidborne M., Eaton V., Bingle C., et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med 162 2 Pt 1 (2000) 755-758
44. Feldmann M., Brennan F.M., Foxwell B.M., and Maini R.N. The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun 3 (2001) 188-199
45. Uson J., Balsa A., Pascual-Salcedo D., Cabezas J.A., González-Tarrio J.M., Martín-Mola E., et al. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 24 11 (1997) 2069-2075
46. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101 2 (1998) 311-320
47. Tilg H., Trehu E., Atkins M.B., Dinarello C.A., and Mier J.W. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83 1 (1994) 113-118
48. Pascual M., Nieto A., Mataran L., Balsa A., Pascual-Salcedo D., and Martín J. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun 1 5 (2000) 338-340
49. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102 7 (1998) 1369-1376
50. Martínez A., Pascual M., Pascual-Salcedo D., Balsa A., Martín J., and De la Concha E.G. Genetic polymorphisms in Spanish rheumatoid arthritis patients: An association and linkage study. Genes Immun 4 2 (2003) 117-121
51. Chernoff A.E., Granowitz E.V., Shapiro L., Vannier E., Lonnemann G., Angel J.B., et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154 10 (1995) 5492-5499
52. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., and Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24 1 (1997) 1-8
53. Braun N., Michel U., Ernst B.P., Metzner R., Bitsch A., Weber F., et al. Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and its influence on the regulation of TNF-alpha production. Neurosci Lett 215 2 (1996) 75-78
54. Padyukov L., Hytonen A.M., Smolnikova M., Hahn-Zoric M., Nilsson N., Hanson L.A., et al. Polymorphism in promoter region of IL-10 gene is associated with rheumatoid arthritis in women. J Rheumatol 31 3 (2004) 422-425
55. Ranganathan P., and McLeod H.L. Methotrexate pharmacogenetics: The first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 54 5 (2006) 1366-1377
56. Dervieux T., Lein D.O., Park G., Barham R., Smith K., and Walsh M. Single nucleotide polymorphisms (SNPs) in the folate/purine synthesis pathway predict methotrexate′s effect in rheumatoid arthritis. Arthritis Reum 48 Suppl 9 (2003) S438
57. Pawlik A., Wrzesniewska J., Fiedorowicz-Fabrycy I., and Gawronska-Szklarz B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42 (2004) 496-503
58. Kang S.S., Zhou J., Wong P.W., Kowalisyn J., and Strokosch G. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductasa. Am J Hum Genet 43 (1988) 414-421
59. Haagsma C.J., Blom H.J., Van Riel P.L., Van′t Hof M.A., Giesendorf B.A., Van Oppenraaij-Emmerzaal D., et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 58 (1999) 79-84
60. Urano W., Taniguchi A., Yamanaka H., Tanaka E., Nakajima H., Matsuda Y., et al. Polymorphisms in the methylenetetrahydrofolate reductasa gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12 (2002) 183-190
61. Taniguchi A., Urano W., Tanaka E., Furihata S., Kamitsuji S., Inoue E., et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genom 17 (2007) 383-390
62. Dervieux T., Greenstein N., and Kremer J. Pharmacogenetic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 54 10 (2006) 3095-3103
63. Berkun D.L., Rubinow A., Orbach H., Aamar S., Grenader T., Abou Atta I., et al. Methotrexate related adverse effects in patients with rheumatoid artritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 63 (2004) 1227-1231
64. Kumagai K., Hiyama K., Oyama T., Maeda H., and Cono N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductasa genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Intl J Mol Med 11 (2003) 593-600
65. Herrlinger K.R., Cummings J.R., Barnardo M.C., Schaw M., Ahmad T., and Jewell D.P. The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genom 15 (2005) 705-711
66. Wessels J.A.M., Van der Kooij S.M., Le Cessie S., Kievit W., Barerra P., Allaart T.W.J., et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 56 6 (2007) 1765-1775
67. Horie N., Aiba H., Oguro K., Hojo H., and Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20 (1995) 191-197
68. DiPaolo A., and Chu E. The role of thymidylate synthase as a molecular biomarker. Clin Cancer Res 10 (2004) 411-412
69. Ulrich C.M., Bigler J., Velicer C.M., Greene E.A., Farin F.M., and Potter J.D. Searching expressed sequence tag databases: Discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 9 (2000) 1381-1385
70. Grzybowska E.A., Wilczynska A., and Siedlecki J.A. Regulatory functions of 3UTRs. Biochem Biophys Res Commun 288 (2001) 291-295
71. Dervieux T., Furst D., Lein D.O., Capps R., Smith K., Walsh M., et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50 (2004) 2766-2774
72. Rains C.P., Noble S., and Faulds D. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 50 (1995) 137-156
73. Pullar T., and Capell H.A. Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review. Drugs 32 Suppl.1 (1986) 54-57
74. Wadelius M., Stjernberg E., Wiholm B.E., and Rane A. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics 10 (2000) 35-41
75. Tanaka E., Taniguchi A., Urano W., Nakajima H., Matsuda Y., Kitamura Y., et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 29 (2002) 2492-2499
76. Ranganathan P. Pharmacogenetics of therapies in rheumatoid arthritis. Drugs today 41 12 (2005) 799-814
77. Krynetski E.Y., Tai H.L., Yates C.R., Fessing M.Y., Loennechen T., Schuetz J.D., et al. Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms. Pharmacogenetics 6 (1996) 279-290
78. Tai H.L., Krynetsky E.Y., Schuetz E.G., Yanishevsky Y., and Evans W.E. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) ancoded by mutant alleles in humans (TPMT*3A, TPMT*2): Mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 94 (1997) 6444-6449
79. Corominas H., Domenech M., Laiz A., Vich I., Geli C., Diaz C., et al. Is thiopurine methyltransferase genetic polymorphism a major factor for with drawal of azathioprine in rheumatoid arthritis patients?. Rheumatology 42 (2003) 40-45
80. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 46 (2002) 1443-1450
81. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004) 1400-1411
82. Greenberg J.D., and Ostrer H. The promise of pharmacogenetics to TNF antagonists in rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases 65 2 (2007) 139-142
83. Ferraccioli G. The possible clinical application of pharmacogenetics in rheumatology. J Rheumatol 30 12 (2003) 2517-2520
84. Lipsky P.E., Van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 22 (2000) 1594-1602
85. Bouma G., Crusius J.B., Oudkerk Pool M., Kolkman J.J., Von Blomberg B.M., Kostense P.J., et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 43 4 (1996) 456-463
86. Callan M.F. Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients. Curr Opin Rheumatol 16 4 (2004) 399-405
87. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44 12 (2001) 2862-2869
88. Baecklund E., Ekbom A., Sparen P., Feltelius N., and Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317 (1998) 180-181
89. Emery P., Van de Putte L.B.A., Van Riel P.L.C.M., Rau R., Schattenkirchner M., and Burmester G.R. Changes in Pro-MMP-1 in relation to standard measures of disease activity over a 6-month treatment period with adalimumab (D2E7) in rheumatoid arthritis. Arthritis Reum 44 Suppl (2001) 215
90. Bresnihan B., Álvaro-Gracía J.M., Cobby M., Doherty M., Domljan Z., Emery P., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41 12 (1998) 2196-2204
91. Cohen S., Hurd E., Cush J., Schiff M., Weinblatt M.E., Moreland L.W., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 3 (2002) 614-624
92. Fleischmann R.M., Schechtman J., Bennett R., Handel M.L., Burmester G.R., Tesser J., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 48 4 (2003) 927-934
93. Guignard S., Dien G., and Dougados M. Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: A case report. Clin Exp Rheumatol 25 5 (2007) 758-759
94. Kalliolias G.D., and Liossis S.N. The future of the IL-1 receptor antagonist anakinra: From rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 17 3 (2008) 349-359
95. Criswell L.A., Lum R.F., Turner K.N., Woehl B., Zhu Y., Wang J., et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 50 9 (2004) 2750-2756
96. Walsh E.C., Mather K.A., Schaffner S.F., Farwell L., Daly M.J., Patterson N., et al. An integrated haplotype map of the human major histocompatibility complex. Am J Hum Genet 73 (2003) 580-590
97. Kang C.P., Lee K.W., Yoo D.H., Kang C., and Bae S.C. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 44 4 (2005) 547-552
98. Fabris M., Tolusso B., Di Pol E., Assaloni R., Sinigaglia L., and Ferraccioli G. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid artritis. J Rheumatol 29 (2002) 1847-1850
99. Schotte H., Schluter B., Drynda S., Willeke P., Tidow N., Assmann G., et al. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 64 4 (2005) 575-581
100. Mugnier B., Balandraud N., Darque A., Roudier C., Roudier J., and Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 48 7 (2003) 1849-1852
101. Cuchacovich M., Ferreira L., Aliste M., Soto L., Cuenca J., Cruzat A., et al. Tumor necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 33 4 (2004) 228-232
102. Fonseca J.E., Carvalho T., Cruz M., Nero P., Sobral M., Mourao A.F., et al. Polymorphism at position-308 of the tumor necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis 64 5 (2005) 793-794
103. Pinto J.A., Rego I., Fernández López C., Freire M., Fernández Sueiro J.L., Blanco F.J., et al. Polymorphisms in genes encoding TNF-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis. J Rheumatol 35 1 (2008) 177-178
104. Camp N.J., Cox A., Di Giovine F.S., McCabe D., Rich W., and Duff G.W. Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. Genes Immun 6 6 (2005) 467-471
105. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Reum 31 (1998) 315-324
106. Choy E.H., and Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344 12 (2001) 907-916
107. Bridges Jr. S.L. The genetics of rheumatoid arthritis: Influences on susceptibility, severity, and treatment response. Curr Rheumatol Rep 1 2 (1999) 164-171
108. Evans W.E., and McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N Eng J Med 348 6 (2003) 538-549
109. Lequerré T., Gauthier-Jauneau A.C., Bansard C., Derambure C., Hiron M., VIttecoq O., et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 8 4 (2006) R105
110. Hirschhorn J.N., Lohmueller K., Byrne E., and Hirschhorn K.A. A comprenhensive review of genetic association studies. Genet Med 4 2 (2002) 45-61